|
Alpha Biologics
|
|
|
Amura
|
|
|
Antitope Limited
Antitope is pioneering a new generation of immunogenicity testing and protein engineering technologies. Our mission is to apply these technologies to create improved non-immunogenic biologics.
Formed in 2004, Antitope offer proprietary technologies as a comprehensive service for evaluating immunogenicity, identifying T cell epitopes, producing humanized antibodies and generating non-immunogenic proteins.
The core proprietary technologies include:
EpiScreen™ for accurately measuring the immunogenicity potential of therapeutic proteins and different formulations, identifying specific T cell epitopes or determining the potential of NCEs to induce late onset allergy like reactions.
Composite Human Antibodies™ to generate humanized, T cell epitope depleted antibodies for therapeutic use.
Composite Proteins™ to generate non-immunogenic proteins with desired biological function for therapeutic use.
|
|
|
ASM Scientific Ltd
|
|
Babraham Bioscience Technologies Limited
Babraham Bioscience Technologies Ltd (BBT) is the wholly owned trading company of the and is the pro-active vehicle through which all commercial opportunities on the Babraham Research Campus are planned and delivered.
|
|
|
Babraham Institute
The Institute is an independent charitable life sciences institute, sponsored by the Biotechnology and Biological Sciences Research Council. It undertakes world-leading innovative research and advanced training with relevance to the biomedical, biotechnological, pharmaceutical and healthcare communities.
The commercialisation of the Institute's research is managed by its wholly-owned trading subsidiary, Babraham Bioscience Technologies Ltd (BBT), a knowledge transfer company, which also manages a BioIncubator facility for small biotech companies. The Babraham Institute, BBT and a number of independent biomedical and biotechnology companies are situated on the Babraham Research Campus, located six miles south-east of Cambridge. Set in the picturesque parkland estate of Babraham Hall, the campus provides an environment that promotes innovation in the biomedical sector and has key role in the development of the Eastern region's biotechnology community.
|
|
|
Bioinnovel Limited
|
|
Cambridge Biotechnology Ltd
|
|
|
Cambridge Theranostics Limited
Cambridge Theranostics was founded in 2002 to commercialize intellectual property relating to lipid oxidation from its founder, Dr Ivan Petyaev. The Company successfully developed Ateronon®/™; the first clinically proven product able to inhibit plasma lipoprotein oxidation. THe active ingredient is a natural product and is licensed to Cambridge Theranostics exclusively by Nestlé.
Cambridge Theranostics recently successfully completed a pre-IPO private placement managed by Charles Stanley Securities, a London stockbroker. The Company focuses on development of its intellectual property and the clinical validation of its products. It has a global network of partners for product manufacture, distribution and marketing.
|
|
|
Colonix Medical Limited
|
|
|
ERBI
Networking and communications in Cambridge and the East of England Bio-community. Our aim is to enhance the growth and development of biotechnology and medtech in the East of England, thereby asserting the region as a world renowned centre of excellence
|
|
Horizon Discovery
Horizon Discovery is a translational genomics company founded in June 2007 and is headquartered at the Babraham Research Campus, Cambridge, UK and with additional research laboratories in Torino, Italy.
The company supplies a wide range of products and services based on Human isogenic cell-lines, which represent accurate models of defined cancer patient populations and their matched normal genetic backgrounds – a missing link in the rational and efficient development of novel targeted anti-cancer agents.
The company has unique IP in the field of gene engineering and is developing new IP via in-house and collbaorative drug discovery programs.
|
|
|
ImmunoBiology Ltd
ImmBio was set up to commercialise advances in the emerging science of Immunobiology. ImmBio's initial focus is the application of its platform technology, Immunovaccination, to develop the next generation of vaccines. ImmBio recently won a DTI SMART award.
|
|
|
Innova Biosciences Ltd
Innova specialises in bioconjugate technology and has recently launched Lightning-Link, a method for labelling biomolecules requiring only 30 seconds hands-on time.
|
|
|
Isogenica
|
|
|
Lectus Therapeutics
|
|
|
MedCell Bioscience Ltd
MedCell Bioscience is a UK based biotech company focussed on harnessing the power of stem cells to provide musculoskeletal regenerative therapeutics.
MedCell was formed in September 2002 as a spin-out from the Institute for Orthopaedics and Musculoskeletal Science (IOMS) and the Royal Veterinary College (RVC) to develop technology for the treatment of tendon and ligament injuries using adult stem cells.
In June 2008 MedCell merged with NovaThera to create a company with the breadth of technologies to become a key player in the regenerative medicine market.
|
|
|
Novexin
Novexin is a biotechnology company developing new technologies with potential to radically change the way in which proteins are produced, particularly proteins of pharmaceutical importance.
|
|
|
Phico Therapeutics Limited
|
|
|
Population Genetics Technologies Limited
|
|
|
Pronostics Ltd
Pronostics is a new and revolutionary medical diagnostics company formed by the merger of SmartBead Technologies Ltd (SBT) and FingerPrint Diagnostics Ltd (FPD) in June 2006. The combination of two advanced technologies makes possible and accelerates the availability of an entirely new class of medical diagnostics, ‘pronostics’, also known as IVD multivariate index assays by the US FDA, based on multiplexed biological profiling.
|
|
|
Senexis
Senexis is a growing, small-molecule drug development company that is committed to revolutionising the treatment and diagnosis of diseases resulting from the inevitable process of ageing. Senexis is advancing a pipeline of novel treatments for diseases resulting from the toxicity of amyloid-like proteins.
|
|
|
Stem Cell Sciences plc
Stem Cell Sciences’ core objective is to develop safe and effective stem cell-based therapies for currently incurable diseases.
|
